— Federal health advisers said Wednesday that a first-of-a-kind drug from Pfizer appears to be safe and efficacious as patients with rheumatoid arthritis,notwithstanding they recommended follow-up studies to gauge the pill's long-term side effects. The Food and Drug Administration's panel of arthritis experts voted 8-2 within favor of Pfizer's tofacitinib as patients who have never responded to an alternatively more other drugs,Cheap Louboutins. The FDA is never essential to imitate the group's counsel,although it constantly does. A final decision namely expected in August. Panelists said the pill could be an important option for patients,but voiced concern over reports of lymphoma and infection among patients taking the pill Assessing the drug's symbol amid those...